Cardiology

Ambient air pollution has become one of the world's greatest killers. But physicians still differ on their involvement in fighting it.

New data shows that an increase in the burden of AF is independently associated with a higher risk of ischemic stroke and arterial thromboembolism in patients who have not received anticoagulant medication.

The investigational new drug application allows the initiation of phase 1/2 clinical trial to assess the safety of BIVV003 in adults.

Pulmonary hypertension is a common complication of CHD but a new Danish study is the first to report on population-based incidence and impact.

Is there a relationship between osteoporosis, cardiovascular disease, and mortality? This new study aimed to find out. 

Susan Weisman, a light chain (AL) amyloidosis caregiver for her husband since 2009, touches on a few of her husband's treatments in an approximate timeline.

The injection therapy was a previously non-approved FDA product that was grandfathered into marketed use for about 4 decades.

Pulmonary arterial hypertension is often complicated by atrial arrhythmias; a new study sheds light on the clinical impact.

Patients treated with dabigatran following myocardial injury after noncardiac surgery were 20% less likely to die of a cardiovascular cause.

For even life-altering conditions such as cardiovascular disease, not enough Americans are taking their medicine. Why?

Patients who abused substances reported significantly greater cardiovascular and all-cause mortality risk from type 1 MI — despite also reporting lower risks for traditional factors.

New data revealed by the Tufts Center for the Study of Drug Development concludes that orphan drug development takes 18% longer than the average time required for other new drugs.

The HeartLight Excalibur Balloon, designed for the treatment of paroxysmal atrial fibrillation, is ultra-compliant and can be resized in real-time.

In an interview with Rare Disease Report, Mathew Maurer, MD, Arnold and Arlene Professor of Cardiology at Columbia University, explained the standard of care and current management tactics for individuals with hATTR Amyloidosis.

The Advisor™ HD Grid Mapping Catheter, Sensor Enabled™ provides physicians with a detailed map of cardiac tissue to allow for more precise ablation therapy.

According to new researche, a widely-used cholesterol-lowering drug increased a precursor of high-density lipoprotein (HDL) in models that mimicked liver cells of patients with Friedrich’s ataxia (FA).

Andexanet alfa showed a median decrease in anti-Factor Xa activity from baseline of 97% for those on rivaroxaban and 92% for those on apixaban.

Dosing of the first patient in the Phase 2 clinical trial of AG10 in patients with ATTR cardiomyopathy, Eidos Therapeutics, Inc. has announced.

Results of a subgroup analysis from the GRIPHON trial are promising for a hard-to-treat population.

The Computed Tomography Angiography device from iSchemaView gives physicians quick, and diverse, options to analyze stroke patient candidates.

If, when, and for how long anticoagulation should be administered in these 3 patients is the challenge in each case. Do you know your guidelines?

A new study finds that the first treatment chosen to treat PAH may help mitigate the burden of all-cause cost of care.

Results of a new study suggest that stroke volume index may be the better hemodynamic variable to monitor in PAH – not cardiac index.

The filing is supported by data from MERIT-1 which showed great improvements in pulmonary vascular resistance and 6-minute walk distance versus ongoing background therapy.

Data from a duo of poster presentations showed icosapent ethyl reduced potentially atherogenic lipid and inflammatory markers in statin-treated patients with reduced kidney function and high triglycerides.